American Hospital Association
Health Research & Educational Trust

Central Line-Associated Bloodstream Infection (CLABSI)


CLABSIs are serious, but preventable infections when evidence-based guidelines for central line insertion and maintenance are properly prioritized and implemented. If not prevented, CLABSIs result in increased length of hospital stay, increased cost and increased patient morbidity and mortality. An estimated 30,100 CLABSIs occur in U.S. intensive care units each year (CDC, 2015), with up to 250,000 occurring across care settings (Klevens et al., 2004). Patient mortality rates associated with CLABSI range from 12 to 25 percent (CDC, 2011) and the cost of CLABSIs range from $3,700 to $36,000 per episode (Scott, 2009).

Between 2008 and 2013, the adoption and implementation of evidence-based practices has been associated with a 46 percent reduction in CLABSIs (CDC, 2014). Nonetheless, further efforts are needed to prevent patient harm, especially in non-critical care settings, including hemodialysis centers and inpatient wards. As almost 32 percent of CLABSIs occur outside the ICU, the spread of ICU successes is necessary to achieve patient safety goals across patient populations. To learn more about how CLABSIs impact patients, listen to Nora's story.


From 2011 to 2014, the AHA/HRET HEN prevented an estimated 893 CLABSIs with an estimated cost savings of over $15 million.


20 percent reduction in CLABSIs by 2019.

Partnership for Patients (PfP) Goal